HEMORHEOLOGICAL PROPERTIES OF THE 5-HT2A-ANTAGONIST OF THE 2-METHOXYPHENYL-IMIDAZOBENZIMIDAZOLE DERIVATIVE OF THE RU-31 COMPOUND AND CYPROHEPTADINE, IN COMPARISON WITH PENTHOXYPHYLLINE

Migraine and its comorbid conditions are pathogenetically associated with many factors, including hemorheological disorders. A class of drugs with a 5-HT2A antagonistic mechanism of action, is promising for the prevention and treatment of migraine attacks and concomitant pathologies.The aim of the research is to study and compare a hemorheological activity of anti-migraine drugs, antagonists of 5-HT2A receptors of cyproheptadine, and a new drug that completed preclinical studies of the 1-(2-diethylaminoethyl)-2-(4-methoxyphenyl)-imidazo[1,2-a]benzimidazole derivative of the RU- 31 compound.Materials and methods. The study of the hemorheological activity of the RU-31 compound and cyproheptadine, was carried out using an experimental model of rabbit blood hyperthermia in vitro. Pentoxifylline was used as a reference drug. In the course of the work, the parameters of blood viscosity, aggregation and deformability of erythrocytes were recorded.Results. It has been established that in the concentration of 1 μM, the RU-31 compounds reduce blood viscosity by 17% at high shear rates, which is comparable with pentoxifylline in the concentration of 100 μM on the activity level. In the concentration of 1 μM, cyproheptadine also causes a general tendency to reduce blood viscosity at high shear rates, being inferior in activity to the RU-31 compound and pentoxifylline. In the concentration of 1 μM, the RU-31 compound has a pronounced effect on the aggregation ability of erythrocytes in autologous plasma, reducing the aggregation rate by 70%, while the level of activity is not inferior to the drug compared to pentoxifylline in the concentration of 100 μM, and surpasses the drug cyproheptadine. For the RU-31 compound and cyproheptadine, no significant effect on the deformability of erythrocytes has been shown.Conclusion. The capacity of cyproheptadine and the RU-31 compound to influence the rheological properties of blood by reducing blood viscosity and aggregation of erythrocytes has been revealed.

COMPUTER SIMULATION OF GLICOPHORIN A AND 4-METHYL-2,6-DIISOBORNILFENOL INTERACTION BY AUTODOCK AND HEXSERVER PROGRAMS

4-methyl-2,6-diisobornilphenol (dibornol) – a promising drug with a hemorheological activity. Glycophorin A is one of erythrocyte membrane proteins involved in the aggregation and possibly mediating rheological effects of dibornol.Objective: to conduct a modeling of the interaction dibornol and glycophorin A by AutoDock and HexServer programs.Material and methods. We used three-dimensional models of molecules dibornol and glycophorin A. Information on the three-dimensional model of glycophorin A was received from the database RCSB Protein Data Bank – 1AFO. Modeling the three-dimensional model of a dibornol (4-methyl-2,6- diisobornilfenol) was modeling by PRODRG Server.Results. This paper presents the results of computer modeling of interaction dibornol and glycophorin A by HexServer and AutoDock programs. We used the electrostatic properties of the molecule glycophorin A, site of interaction is position chain A VAL83, chain B – ALA82, GLY83, GLY86, THR87. The energy of binding was –6.73 kcal/mol by AutoDock program, HexServer – –2.89 kcal/mol. The charge of the molecular complex dibornol-glycophorin A decreased to –4.126 (the charge of the native molecule glycophorin A – –4.003).Conclusion. Integrated use of the program AutoDock and HexServer helps significantly reduce the time and computational resources in the modeling. The study identified the amino acids that may play a key role in the interaction with dibornol glycophorin A. This study has given us reason to believe that as a result of such interaction dibornol may prevent adhesion of red blood cells.